Healthcare / BiotechnologyShenzhen
$2.76
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-20.2M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$365M
P/E
30.7x
↑EV/EBITDA
6.0x
↓ROE
6.9%
↑Gross Margin
81.0%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.1%
FCF CAGR
—
FCF margin
15.5%
FCF / Net income
4.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $177.0M · net income $6.5M · FCF $27.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $177.0M | $177.0M | $98.7M | $110.0M | $166.5M |
| Net Income | $6.5M | $6.5M | $-131.5M | $-157.0M | $-595.0M |
| EBITDA | $42.7M | $42.7M | $-150.3M | $-160.0M | $-600.5M |
| EPS | 0.05 | 0.05 | -0.99 | -1.19 | -4.07 |
| Gross Margin | 81.0% | 81.0% | 76.9% | 57.6% | 37.4% |
| Operating Margin | 7.3% | 7.3% | -35.9% | -43.3% | -25.0% |
| Net Margin | 3.7% | 3.7% | -133.3% | -142.7% | -357.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.21 | 0.05 | 0.03 |
| Current Ratio | 1.10 | 1.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $27.4M | $27.4M | $-20.2M | $-36.4M | $-33.9M |
| Returns | |||||
| ROE | 6.9% | 6.9% | -205.4% | -80.3% | -168.8% |
| Valuation | |||||
| P/E | 30.67 | 30.67 | — | — | — |
| EV/EBITDA | 5.97 | 5.97 | — | — | — |
| P/B | 3.90 | 3.90 | 25.86 | 11.07 | 3.99 |
| Growth & Yield | |||||
| Revenue Growth | 79.4% | 79.4% | -10.3% | -33.9% | — |
| EPS Growth | 104.9% | 104.9% | 16.2% | 70.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
71.0%
EPS terminal req.
$0.24
Spread vs growth
34.0%
5Y implied EPS CAGR
43.3%
EPS terminal req.
$0.30
Spread vs growth
61.6%
10Y implied EPS CAGR
25.6%
EPS terminal req.
$0.48
Spread vs growth
79.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-67.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.99 → 0.05
Residual
-67.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.